| 8.30 | |
Registration & Coffee
|
| 9.00 | |
Chairman's Opening RemarksRichard Bax, Senior Partner, TranScrip Partners View Bio |
| 9.10 |  |
The war you cannot win - but survive: how the pharma industry is mobilising to get the pipeline goingRichard Bergstrom, Director General, EFPIA View Bio
- Pooling resources in public-private partnerships with the European Commision (IMI and Horizon 2020)
- Towards reasonable and predicatble regulatory requirements
- Bringing back old compound: what incentives are used?
- How to preserve new antibiotics? A global compact for controlled use?
|
| 9.50 | |
Update on current R&D and the Regulatory EnvironmentRichard Bax, Senior Partner, TranScrip Partners View Bio
- Big and little pharma activity and progress
- Report on REACT, BSAC, IDSA, Barda FP7 EU and Innovative Medicines Initiative
- A developers view on the EMA workshop on the development of new antibacterial medicines - October 2012
- Prospects for the future
|
| 10.10 | |
Round Table DiscussionRichard Bax, Senior Partner, TranScrip Partners View Bio Richard Bergstrom, Director General, EFPIA View Bio Ursula Theuretzbacher, Founder, Center For Anti-Infective Agents Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision View Bio |
| 10.45 | |
Morning Coffee
|
| 11.00 | |
The use of isogenic strains in antimicrobial drug discoveryPeter Warn, Chief Scientific Officer, Euprotec View Bio
- Highly characterised isogenic strains
- Uses of isogenic strains in vivo systems
- PK/PD with isogenic strains
|
| 11.40 | |
An update on current issues and progress in C. difficile disease (CDAD)William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center View Bio
- A brief history and review
- The changing epidemiology and resistance development in CDAD
- Transmission, Virulence factors and clinical manifestations
- Surveillance, diagnosis and clinical testing
- Prevention, emerging therapies and potential for efficacy
|
| 12.20 | |
Networking Lunch
|
| 13.20 | |
Case study: development candidate BAL30072Malcolm Page, Head of Biology, Basilea Pharmaceutica Ltd View Bio
• .Activity of BAL30072 against multi-drug resistant Gram-negative bacteria
• .Activity of BAL30072 against Burkholderia pseudomallei and B. mallei
• .Combined effects of BAL30072 and carbapenems in vitro
• .Enhanced activity of BAL30072 and meropenem in animal infection models
|
| 14.00 | |
The design of a novel class of antibiotics for the treatment of highly resistant gram-negativesErin Duffy, Chief Scientific Officer, Rib-X Pharmaceuticals View Bio
An exploration of the process to engineer new antibiotics for the worst bacteria
Overcoming known resistance mechanisms
Achieving the desired safety window
|
| 14.40 | |
Armeniaspiroles : new class of antibacterialsCedric Couturier, Head of Laboratory, Sanofi View Bio
• Gram-positive bacterial pathogens
• Fermentation, structure isolation and characterization
• Total synthesis
• Natural products
|
| 15.20 | |
Afternoon Tea
|
| 15.40 | |
Discovery of Discovery and development of Simeprevir (TMC435) and TMC647055, two novel direct antiviral agents targeting the Hepatitis C VirusPierre Raboisson, Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development View Bio
HepatitisC virus (HCV)-encoded NS3/4A protease and NS5B polymerase are essentail for viral replication and represent two attractive targets for therapeutic intervention in HCV-infected patients
Both NS3/4A protease and NS5B non-nucleoside inhibitors are able to decrease HCV viremia, either as monotherapy or in addition to the current standard of care therapy
Simeprevir (TMC435) and TMC647055 are two potent and selective inhibitors of HCV replication in genotype 1b replicon cells with EC50 values of 8 nM and 82 nM, respectively
Combination of these two drug candidates in an interferon-free setting is currently under investigation in the clinic
|
| 16.20 | |
GC-072: A novel resistance-breaking oxoquinolizineJutta Heim, Professor of Biotechnology chief scientific officer, Evolva SA View Bio
• Novel oxoquinolizine
• Broad-spectrum and potent topisomerase inhibitor
• Different binding site than quinolones
• Excellent in vitro coverage of Gram-positive and Gramnegative MDR pathogens
• Favorable PK and initial Tox profile
• Active in in vivo infection models, oral and IV
|
| 17.00 | |
Antibacterial Developments in Tuberculosis ResearchAnthony Coates, Professor, St George's, University of London View Bio
- New models are needed for antibacterial development in TB
- Novel in vitro models which mimic TB persister bacteria
- New murine models which are more similar to human tuberculosis than current models
|
| 17.40 | |
Chairman’s Closing Remarks and Close of Day One
|